Chimeric virus-like particles incorporating fusion GPI anchored GM-CSF and IL-4 conjugates

Patent metadata

Field	Value
Publication number	US-10072058-B2
Application number	US-201615142169-A
Country	US
Kind code	B2
Filing date	Apr 29, 2016
Priority date	Apr 29, 2015
Publication date	Sep 11, 2018
Grant date	Sep 11, 2018

Abstract

This disclosure relates to a GM-CSF and IL-4 conjugate fused to a glycolipid (GPI)-anchoring sequence that is incorporated into chimeric virus-like particles (VLPs) enriched with a viral protein, e.g., viral envelope protein or HIV envelope protein. In certain embodiments, the disclosure relates to methods of immunization with the chimeric VLPs disclosed herein. In certain embodiments, the disclosure relates to methods of immunization with disclosed HIV antigen containing VLPs through an intramuscular priming-intranasal boosting immunization route.

First claim

The invention claimed is:

1. A nucleic acid encoding a fusion protein comprising the amino acid sequence of SEQ ID NO: 7.

2. A vector comprising the nucleic acid of claim 1 in operable combination with a promoter sequence.

3. An in vitro cell comprising the vector of claim 2 .

4. A chimeric virus-like particle comprising the fusion protein encoded by the nucleic of claim 1 .

5. The chimeric virus-like particle of claim 4 , further comprising a viral envelope protein.

6. The chimeric virus-like particle of claim 5 , wherein the viral envelope protein is an HIV envelope protein.

7. The chimeric virus-like particle of claim 6 , wherein the viral envelope is gp160, gp120, or gp41.

8. An in vitro cell comprising the nucleic acid of claim 1 .

9. A nucleic acid encoding a fusion protein comprising a variant amino acid sequence of SEQ ID NO: 7, wherein the variant comprises one conserved amino acid substitution.

10. A vector comprising the nucleic acid of claim 9 in operable combination with a promoter sequence.

11. An in vitro cell comprising the vector of claim 10 .

12. A chimeric virus-like particle comprising the fusion protein encoded by the nucleic of claim 9 .

13. The chimeric virus-like particle of claim 12 , further comprising a viral envelope protein.

14. The chimeric virus-like particle of claim 13 , wherein the viral envelope protein is an HIV envelope protein.

15. The chimeric virus-like particle of claim 14 , wherein the viral envelope is gp160, gp120, or gp41.

16. An in vitro cell comprising the nucleic acid of claim 9 .

Assignees

• Univ Emory
• Childrens Healthcare Atlanta Inc

Inventors

• Wang Baozhong
• Compans Richard W
• Galipeau Jacques
• Deng Jiusheng

Classifications

• C12N2740/16222

  New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes · CPC title

• C12N2740/16034

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• C12N15/79

  Vectors or expression systems specially adapted for eukaryotic hosts · CPC title

• C12N15/63

  Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression · CPC title

• C07K2319/912

  containing a GPI (phosphatidyl-inositol glycane) anchor · CPC title